CSP
1 min read
22

Fondia Plc: Share repurchase 31.10.2024

October 31, 2024
0

Reading Time: < 1 minute Fondia Plc Company release 31.10.2024 at 6.45 p.m. EET   Fondia – Acquisition of own shares 31.10.2024   Fondia Plc   First North Finland   Date 31.10.2024 Exchange transactions Buy Share class FONDIA Amount, shares 276 Average price/share, EUR 6,092029

Continue Reading
CSP
3 min read
14

Balder announces directed issue of 18 million Class B shares raising proceeds of a little less than SEK 1.5 billion

October 31, 2024
0

Reading Time: 2 minutes The board of directors of Fastighets AB Balder (publ) (“Balder”) has, based on the authorization granted by the annual general meeting on 3 May 2024, resolved to carry out a directed cash issue of 18 million Class B shares at a subscription

Continue Reading
CSP
3 min read
15

Osseointegration for Amputees Makes its Education Forum Debut at OTA 2024

October 31, 2024
0

Reading Time: 2 minutes Integrum AB (publ), ticker INTEG, the medical technology company that provides the bone-anchored OPRA® Implant System to amputees announces its education forum debut. Integrum’s U.S. team recently exhibited at the Orthopedic Trauma Association (OTA) annual meeting, held last week in Montreal.

Continue Reading
CSP
1 min read
16

Change in the number of shares and votes in Sinch AB (publ)

October 31, 2024
0

Reading Time: < 1 minute Stockholm, Sweden – 31 October 2024 – Sinch AB (publ), which is pioneering the way the world communicates through its Customer Communications Cloud, today announces that the number of shares and votes in Sinch AB (publ), registration number 556882-8908 (“Sinch”),

Continue Reading
CSP
5 min read
132

Biosergen Completes First Cohort of BSG005 Clinical Trial, Shows Promising Potential in Drug-Resistant Fungal Infections

October 31, 2024
0

Reading Time: 4 minutes October 31, 2024 – Biosergen AB (“Biosergen”), a clinical-stage biotechnology company developing therapies for life-threatening fungal diseases, today announced the completion of treatment for the first cohort of patients in its proof-of-concept clinical trial for its antifungal drug-candidate BSG005. The cohort

Continue Reading
CSP
1 min read
41

Change in Wetteri Plc’s Management Team

October 31, 2024
0

Reading Time: < 1 minute Wetteri Plc  Stock Exchange Release 31 October 2024 at 16.30 Sanna Räsänen, member of the management team of Wetteri Plc, HR and Communications Director, has resigned from her position. Räsänen will continue to work for Wetteri until 30th November 2024,

Continue Reading
CSP
3 min read
33

Diagonal announces first pilot test at a stud with LAMPlify®

October 31, 2024
0

Reading Time: 2 minutes Read original Diagonal Bio AB (publ) (“Diagonal Bio” or “the Company”) announces a partnership with Gocksta Stud (Gocksta Stuteri), led by Anne-Sophie Thiam, to conduct a three-month pilot study, which begins immediately. This pilot test will evaluate LAMPlify’s potential for rapid detection

Continue Reading
Paige Spiranac Expands SportsGrid’s Content Portfolio with Exclusive Sports and Casino-Themed Shows
CSP
2 min read
37

Paige Spiranac Expands SportsGrid’s Content Portfolio with Exclusive Sports and Casino-Themed Shows

October 31, 2024
0

Reading Time: 2 minutes SportsGrid, the leading free ad supported television network in the sports genre, proudly announces a multi-year partnership with former professional golfer and social media’s most followed golf personality and social media sensation Paige Spiranac. Under this agreement, Spiranac will lead exclusive

Continue Reading
CSP
6 min read
43

Casino Etiquette: 75% of Players Make Mistakes on Their First Visit

October 31, 2024
0

Reading Time: 4 minutes Did you know? 78% of first-time visitors to a casino are unaware of the tipping culture. 60% of new players don’t realise that using their phones at the table is prohibited. 35% of newcomers have been asked to leave a game for

Continue Reading
CSP
11 min read
55

Lundbeck announces positive results from phase III pivotal trial (SUNRISE) of Vyepti® (eptinezumab) in migraine prevention

October 31, 2024
0

Reading Time: 8 minutes Vyepti® confirms efficacy in new phase III pivotal SUNRISE trial, meeting primary endpoint with statistically significant reductions in mean monthly migraine days compared with placebo Vyepti® met all key secondary efficacy endpoints in the SUNRISE trial, and the treatment was generally

Continue Reading